BLACK DIAMOND THERAPEUTICS I's ticker is BDTX and the CUSIP is 09203E105. A total of 73 filers reported holding BLACK DIAMOND THERAPEUTICS I in Q2 2022. The put-call ratio across all filers is 1.57 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,711 | +2751.7% | 596 | +4866.7% | 0.00% | – |
| Q2 2023 | $60 | -99.8% | 12 | -99.9% | 0.00% | – |
| Q1 2023 | $24,171 | +4.8% | 12,789 | -0.2% | 0.00% | – |
| Q4 2022 | $23,065 | -7.7% | 12,814 | -15.1% | 0.00% | – |
| Q3 2022 | $25,000 | -79.5% | 15,086 | -69.7% | 0.00% | – |
| Q2 2022 | $122,000 | -24.2% | 49,725 | -14.6% | 0.00% | – |
| Q1 2022 | $161,000 | -49.1% | 58,239 | -1.5% | 0.00% | – |
| Q4 2021 | $316,000 | +0.6% | 59,125 | +59.1% | 0.00% | – |
| Q3 2021 | $314,000 | -44.9% | 37,156 | -20.7% | 0.00% | – |
| Q2 2021 | $570,000 | -55.3% | 46,832 | -10.9% | 0.00% | – |
| Q1 2021 | $1,276,000 | -31.0% | 52,582 | -8.9% | 0.00% | – |
| Q4 2020 | $1,849,000 | +110.4% | 57,697 | +98.5% | 0.00% | – |
| Q3 2020 | $879,000 | +75.4% | 29,063 | +144.6% | 0.00% | – |
| Q2 2020 | $501,000 | +76.4% | 11,881 | +4.3% | 0.00% | – |
| Q1 2020 | $284,000 | – | 11,388 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| NEA Management Company, LLC | 3,449,845 | $5,830,000 | 0.29% |
| K2 PRINCIPAL FUND, L.P. | 1,031,511 | $1,743,000 | 0.20% |
| Boxer Capital, LLC | 2,014,858 | $3,405,000 | 0.19% |
| DAFNA Capital Management LLC | 313,600 | $530,000 | 0.14% |
| Newtyn Management, LLC | 350,000 | $592,000 | 0.13% |
| Artal Group S.A. | 1,646,517 | $2,783,000 | 0.12% |
| Bellevue Group AG | 4,717,113 | $7,972,000 | 0.11% |
| MPM BioImpact LLC | 239,888 | $405,000 | 0.10% |
| RA Capital Management | 2,589,904 | $4,377,000 | 0.09% |
| Beacon Capital Management, LLC | 35,615 | $88,000 | 0.03% |